methyl 2-(4-(trifluoromethylsulfonyloxy)phenyl)acetate | 147283-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-(trifluoromethylsulfonyloxy)phenyl)acetate
• 英文别名: (4-Trifluoromethanesulfonyloxy-phenyl)-acetic acid methyl ester；Methyl 2-{4-[(trifluoromethyl)sulfonyloxy]phenyl}acetate；methyl 2-[4-(trifluoromethylsulfonyloxy)phenyl]acetate
• CAS: 147283-85-0
• 化学式: C₁₀H₉F₃O₅S
• 分子量: 298.24
• InChiKey: VCTILVYWXPEVHY-UHFFFAOYSA-N

物化性质

• 沸点：
  327.9±42.0 °C(Predicted)
• 密度：
  1.464±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-(trifluoromethylsulfonyloxy)phenyl)acetate 在 palladium on activated charcoal 乙酸铵 、 magnesium 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以83%的产率得到苯乙酸甲酯
  参考文献：
  名称：

  在NH（4）OAc存在下，使用Mg金属和MeOH进行Pd / C催化的苯酚衍生物的脱氧。

  摘要：

  开发了一种在室温下使用Mg金属在MeOH中的Pd / C催化的经由芳基三氟甲磺酸酯或甲磺酸酯对酚羟基进行脱氧的方法。NH 4 OAc的添加显着影响反应性和反应速率。该方法对于在非常温和的反应条件下提供对环境无害且可广泛应用的酚醇去除方法特别有吸引力。

  DOI：

  10.1021/ol060045q
• 作为产物：
  描述：

  对羟基苯乙酸 在 硫酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 9.0h， 生成 methyl 2-(4-(trifluoromethylsulfonyloxy)phenyl)acetate
  参考文献：
  名称：

  3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2

  摘要：

  A series of PPARdelta-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARdelta agonist with good in vivo PK properties in mouse (C(max)=5.1 microM, t(1/2)=3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARdelta is discussed.

  DOI：

  10.1016/j.bmcl.2006.08.052

文献信息

• First Enantioselective Total Synthesis of (−)-Tejedine
  作者：You-Chu Wang、Paris E. Georghiou

  DOI：10.1021/ol0261635

  日期：2002.8.1

  [structure: see text] The first enantioselective total synthesis of (-)-tejedine (1) is reported. Tejedine is a seco-bisbenzyltetrahydroisoquinoline isolated in 1998 as a minor component from Berberis vulgaris. The synthesis was achieved using a strategy employing four key steps, including a chiral auxiliary-assisted diastereoselective Bischler-Napieralski cyclization.

  [结构：见正文]报告了（-）-tejedine（1）的第一个对映选择性全合成。Tejedine是一种1998年从小Ber小isolated中提取的次要成分的癸二双苄基四氢异喹啉。合成是通过采用四个关键步骤的策略实现的，包括手性辅助非对映选择性Bischler-Napieralski环化。
• Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
  申请人：——

  公开号：US20020049236A1

  公开（公告）日：2002-04-25

  There is disclosed a genus of non-peptidyl compounds, wherein said compounds are VLA-4 inhibitors useful in treating inflammatory, autoimmune, and respiratory diseases, and wherein said compounds comprise a compound of Formula (1.0.0): 1 and pharmaceutically acceptable salts and other prodrug derivatives thereof, wherein: A is (C 1 -C 6 ) alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl optionally substituted with 0 to 3 R 9 ; or is a member selected from the group consisting of the following radicals: A 1 -NHC(═O)NH-A 2 -, A 1 -NHC(═O)O-A 2 -, A 1 -OC(═O)NH-A 2 -, A 1 -NHSO 2 NH-A 2 -, A 1 -NHC(═O)-A 2 -, A 1 -C(═O)NH-A 2 -, A 1 -NHSO 2 -A 2 -, A 1 -SO 2 NH-A 2 -, A 1 -(CH 2 ) r -A 2 -, where A 1 and A 2 are each independently selected from the group consisting of hydrogen, aryl, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, cycloalkyl, heteroaryl, and heterocyclyl substituted with 0 to 3 R 9 ; B is a member independently selected from the group consisting of the following: 2 E is a single bond; —O—; —NR 10 —; —CH═CH—; —CC—; —S(═) q ; —CR 11 R 12 NR 10 —; or —CR 11 R 12 ; X is —O—; —C(═O)—; —S(═O) q —; or —NR 10 —; X 1 , X 2 and X 3 are each independently selected from the group consisting of CH, CR 9 or N; Y is a single bond; —C(═O)—; —C(═S)—; or —S(═O) 2 —; R 7 is (C 1 -C 6 ) alkyl; (CH 2 ) k OR 5 ; (CH 2 ) k NR 6 C(═O)R 5 ; (CH 2 ) k NR 6 C(═O)OR 5 ; (CH 2 ) k NR 6 SO 2 R 5 ; (CH 2 ) k NR 6 R 5 ; F; CF 3 ; OCF 3 ; aryl, substituted with 0 to 3 R 9 ; heterocyclyl, substituted with 0 to 3 R 9 ; heteroaryl, substituted with 0 to 3 R 9 ; cycloalkyl, substituted with 0 to 3 R 9 ; or R 7 may be taken together with R 8 to form a cycloalkyl or heterocyclyl ring; or R 7 may be taken together with R 11 to form a cycloalkyl or heterocyclyl ring; and R 8 is hydrogen; F; (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkoxy.

  本发明涉及一类非肽类化合物，其中这些化合物是VLA-4抑制剂，用于治疗炎症性、自身免疫和呼吸道疾病，这些化合物包括如下式（1.0.0）的化合物： 1 以及其药学上可接受的盐和其他前药衍生物，其中： A为（C 1 -C 6 ）烷基，环烷基，芳基，杂芳基或杂环烷基，可选地取代为0至3个R 9 ；或者是从以下基团中选择的成员：A 1 -NHC(═O)NH-A 2 -，A 1 -NHC(═O)O-A 2 -，A 1 -OC(═O)NH-A 2 -，A 1 -NHSO 2 NH-A 2 -，A 1 -NHC(═O)-A 2 -，A 1 -C(═O)NH-A 2 -，A 1 -NHSO 2 -A 2 -，A 1 -SO 2 NH-A 2 -，A 1 -(CH 2 ) r -A 2 -，其中A 1 和A 2 各自独立地选择自氢，芳基，（C 1 -C 6 ）烷基，（C 2 -C 6 ）烯基，（C 2 -C 6 ）炔基，环烷基，杂芳基和杂环烷基，取代为0至3个R 9 ； B是独立地从以下成员中选择的： 2 E是单键；—O—；—NR 10 —；—CH═CH—；—CC—；—S(═) q ；—CR 11 R 12 NR 10 —；或—CR 11 R 12 ； X是—O—；—C(═O)—；—S(═O) q —；或—NR 10 —；X 1 ，X 2 和X 3 各自独立地选择自CH，CR 9 或N；Y是单键；—C(═O)—；—C(═S)—；或—S(═O) 2 —；R 7 是（C 1 -C 6 ）烷基；（CH 2 ） k OR 5 ；（CH 2 ） k NR 6 C(═O)R 5 ；（CH 2 ） k NR 6 C(═O)OR 5 ；（CH 2 ） k NR 6 SO 2 R 5 ；（CH 2 ） k NR 6 R 5 ；F；CF 3 ；OCF 3 ；芳基，取代为0至3个R 9 ；杂环烷基，取代为0至3个R 9 ；杂芳基，取代为0至3个R 9 ；环烷基，取代为0至3个R 9 ；或R 7 可以与R 8 一起形成环烷基或杂环烷基环；或R 7 可以与R 11 一起形成环烷基或杂环烷基环；而R 8 是氢；F；（C 1 -C 6 ）烷基或（C 1 -C 6 ）烷氧基。
• Catalytic Enantio- and Diastereoselective Cyclopropanation of 2-Azadienes for the Synthesis of Aminocyclopropanes Bearing Quaternary Carbon Stereogenic Centers
  作者：Xinxin Shao、Steven J. Malcolmson

  DOI：10.1021/acs.orglett.9b02692

  日期：2019.9.20

  We report the catalytic enantio- and diastereoselective preparation of aminocyclopropanes by the cyclopropanation of terminal and (Z)-internal 2-azadienes with donor/acceptor carbenes derived from α-diazoesters. The resulting cyclopropanes bear quaternary carbon stereogenic centers vicinal to the amino-substituted carbon and are formed as a single diastereomer in up to 99:1 er and 97% yield with 0

  我们报道了通过末端和( Z )-内部2-氮杂二烯与源自α-重氮酯的供体/受体卡宾的环丙烷化，催化对映和非对映选择性制备氨基环丙烷。所得环丙烷带有与氨基取代碳相邻的季碳立构中心，并以高达 99:1 er 和 97% 产率形成单一非对映异构体，其中使用 0.5 mol% 的 Rh 2 (DOSP) 4 和仅1.5当量的重氮试剂。内部氮杂二烯的转化提供了具有三个连续立体中心的环丙烷。
• Heterocyclic amides
  申请人：Zeneca Limited

  公开号：US05521179A1

  公开（公告）日：1996-05-28

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新颖的杂环酰胺，它们是式I所示的1-吡啶乙酰胺化合物，这些化合物是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要这种抑制作用时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE相关疾病。该发明还包括在合成这些杂环酰胺过程中有用的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。
• Mechanistic Study of a Pd/C-Catalyzed Reduction of Aryl Sulfonates Using the Mg–MeOH–NH4OAc System
  作者：Akinori Mori、Tomoteru Mizusaki、Takashi Ikawa、Tomohiro Maegawa、Yasunari Monguchi、Hironao Sajiki

  DOI：10.1002/chem.200601184

  日期：2007.2.2

  method for the deoxygenation of phenolic hydroxy groups via aryl triflates or mesylates has been established by using a combination of Pd/C-Mg-MeOH. The addition of NH(4)OAc to the system markedly accelerated the reaction rate and expanded the scope of the reaction. Mechanistic studies suggested that a single-electron transfer process from the Pd(0) center to the benzene ring is involved in the reduction

  已经通过使用Pd / C-Mg-MeOH的组合物建立了经由芳基三氟甲磺酸酯或甲磺酸酯使酚羟基脱氧的方法。NH（4）OAc添加到系统中明显加快了反应速度，扩大了反应范围。机理研究表明，从Pd（0）中心到苯环的单电子转移过程涉及芳基磺酸盐的还原，并且NH（4）OAc用作Mg盐的增溶剂和Hg的促进剂。电子转移，从而增强了反应过程。我们的方法也适用于以CH（3）OD为溶剂和氘源的苯衍生物的区域选择性氘化：原始羟基可以被氘原子有效地取代。